ClinicalTrials.gg

Program

CT-P43

Its studies are mostly in Psoriasis, led by Celltrion.

Furthest: phase 3, since Dec 13, 20203 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Celltrion30 open or runningphase 3since Dec 13, 2020Jun 8, 2020none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 8, 2020First study: phase 1 study in Healthy SubjectsFirst studyNCT04428814 · 271 enrolled · New Zealand
  2. Dec 13, 2020Phase 3 study in PsoriasisNCT04673786 · 509 enrolled · Estonia
  3. Apr 23, 2025Phase 1 study in Healthy Male SubjectsNCT06951828 · 162 enrolled · South Korea

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06951828Healthy Male Subjects · South Korea1CompletedNov 26, 2025162
NCT04673786Psoriasis · Estonia3CompletedAug 4, 2021509
NCT04428814Healthy Subjects · New Zealand1CompletedFeb 24, 2021271

How it is read

Names in the registry

  • “CT-P43”, 4 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.